Trends in the treatment for patients with cancer are shifting towards earlier intervention, with effective therapies like immunotherapy moving into neoadjuvant stages for improved outcomes. However, Geoffrey D. Moorer, MD, believes that challenges remain in ensuring wider access to sequencing and overcoming data complexity.
While the future holds immense potential for artificial intelligence to revolutionize treatment planning, for now, the focus lies on maximizing access to existing advancements and prioritizing comprehensive diagnostics for all patients with advanced cancer.
In an interview with Targeted OncologyTM, Geoffrey D. Moorer, MD, medical oncologist at Virginia Cancer Specialists, discussed recent trending topics in the field of oncology among hospital tumor boards and committees. Learn more here
